Detail akcie Neurocrine Bios online

Business Summary: Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Neurocrine Biosciences, Inc. revenues increased 26% to $1.73B. Net income increased from $102M to $238.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Acquired in-process research and develop decrease of 93% to $9.5M (expense), Investment income and other, net increase of 86% to $69.6M (income).